JamesMechamFergusonMD

PubMed

• High-dose desvenlafaxine in outpatients with major depressive disorder.
  Ferguson, J. M., Tourian, K. A., Rosas, G. R.> ;CNS Spectr. 2012 Sep
• The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
  Keller, M.B., Trivedi, M.H., Thase, M.E., Shelton, R.C., Kornstein, S.G., Nemeroff, C.B., Friedman, E.S., Gelenberg, A.J., Kocsis, J.H., Dunner, D.L., Dunlop, B.W., Hi...> ;Biol Psychiatry. 2007 Dec 15
• The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
  Keller, M.B., Trivedi, M.H., Thase, M.E., Shelton, R.C., Kornstein, S.G., Nemeroff, C.B., Friedman, E.S., Gelenberg, A.J., Kocsis, J.H., Dunner, D.L., Hirschfeld, R.A....> ;J Clin Psychiatry. 2007 Aug
• Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.
  Kocsis, J.H., Thase, M.E., Trivedi, M.H., Shelton, R.C., Kornstein, S.G., Nemeroff, C.B., Friedman, E.S., Gelenberg, A.J., Dunner, D.L., Hirschfeld, R.A., Rothschild, ...> ;J Clin Psychiatry. 2007 Jul
• 95 citations
  An open-label, flexible-dose study of memantine in major depressive disorder.
  James M. Ferguson, Richard N. Shingleton> ;Clinical Neuropharmacology. 2007 May 1
• 21 citations
  Relapse Prevention of Panic Disorder in Adult Outpatient Responders to Treatment With Venlafaxine Extended Release
  James M. Ferguson, Arif Ullah Khan, Richard Mangano, Richard Entsuah, Evan Tzanis> ;The Journal of Clinical Psychiatry. 2007 Jan 15
• Cytogenetic analysis of obsessive-compulsive disorder (OCD): identification of a FRAXE fragile site.
  Wang, Q., Gu, Y., Ferguson, J.M., Chen, Q., Boatwright, S., Gardiner, J., Below, C., Espinosa, J., Nelson, D.L., Shaffer, L.G.> ;Am J Med Genet A. 2003 Apr 1
• The antidepressant efficacy of reboxetine in patients with severe depression.
  Montgomery, S., Ferguson, J.M., Schwartz, G.E.> ;J Clin Psychopharmacol. 2003 Feb
• Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.
  Ferguson JM, Mendels J, Schwart GE> ;Int Clin Psychopharmacol. 2002-03-01
• Citalopram treatment of paroxetine-intolerant depressed patients.
  Thase, M.E., Ferguson, J.M., Lydiard, R.B., Wilcox, C.S.> ;Depress Anxiety. 2002
• SSRI Antidepressant Medications: Adverse Effects and Tolerability.
  Ferguson, J.M.> ;Prim Care Companion J Clin Psychiatry. 2001 Feb
• Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.
  Ferguson JM, Shrivastava RK, Stahl SM, Hartford JT, Borian F, Ieni J, McQuade RD, Jody D> ;J Clin Psychiatry. 2001-01-01
• Depression: Diagnosis and Management for the Primary Care Physician.
  Ferguson, J.M.> ;Prim Care Companion J Clin Psychiatry. 2000 Oct
• Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. Prothiaden Collaborative Study Group.
  Ferguson JM, Mendels J, Manowitz NR> ;J Clin Psychiatry. 1994-06-01
• Treatment of bulimia with bupropion: a multicenter controlled trial.
  Horne RL, Ferguson JM, Pope HG, Hudson JI, Lineberry CG, Ascher J, Cato A> ;J Clin Psychiatry. 1988-07-01
• Pharmacokinetics of fluoxetine in elderly men and women.
  Ferguson, J. M., Hill, H.> ;Gerontology. 2006
• Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
  Clayton, A. H., Zajecka, J., Ferguson, J. M., Filipiak-Reisner, J. K., Brown, M. T., Schwartz, G. E.> ;Int Clin Psychopharmacol. 2003 May
• Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients.
  Ferguson, J. M., Wesnes, K. A., Schwartz, G. E.> ;Int Clin Psychopharmacol. 2003 Jan
• Join now to see all